Download PDF

1. Company Snapshot

1.a. Company Description

Cryo-Cell International, Inc.engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use.It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.


The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells.It stores approximately 500,000 cord blood and cord tissue stem cells worldwide.The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.


Cryo-Cell International, Inc.was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Show Full description

1.b. Last Insights on CCEL

Cryo-Cell International, Inc.'s recent performance was negatively impacted by a 3% decline in consolidated revenues, which fell to $7.83 million from $8.07 million in the same period last year. The company's fiscal third quarter 2025 results, announced on October 15, 2025, revealed a decrease in revenue, potentially raising concerns about the company's growth trajectory. With no mention of new product launches or acquisitions, the decline in revenue may be attributed to evolving business conditions.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial Results

Oct -15

Source: businesswire.com

Card image cap

Cryo-Cell International, Inc. Provides Dividend Update

Aug -14

Source: businesswire.com

Card image cap

Cord Blood Banking Leader Cryo-Cell Announces Regular Quarterly Cash Dividend and Pause of Strategic Initiatives

Jan -29

Source: businesswire.com

Card image cap

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results

Apr -15

Source: businesswire.com

Card image cap

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2023 Financial Results

Oct -12

Source: businesswire.com

Card image cap

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2023 Financial Results

Jul -14

Source: businesswire.com

Card image cap

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2023 Financial Results

Apr -21

Source: businesswire.com

Card image cap

Cryo-Cell International: A Stable Business Paired With An Upcoming Catalyst

Feb -11

Source: Seeking Alpha

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (6.00%)

6. Segments

Umbilical Cord Blood and Cord Tissue Stem Cell Service

Expected Growth: 6%

Increasing demand for regenerative medicine, growing awareness of stem cell therapy, rising private banking, and expanding research in cord blood and tissue applications drive growth in Cryo-Cell's umbilical cord blood and cord tissue stem cell service, with a growth rate of 6.

Public Cord Blood Banking

Expected Growth: 5%

Increasing demand for stem cell therapies, growing awareness of cord blood banking, expanding insurance coverage, and strategic partnerships drive growth in public cord blood banking. Cryo-Cell International, Inc.'s leadership in the market, coupled with its innovative storage methods and expanding global presence, contribute to its 5% growth rate.

PrepaCyte Cord Blood

Expected Growth: 7%

Strong demand for cord blood stem cells in regenerative medicine, increasing awareness of newborn stem cell preservation, and Cryo-Cell's market leadership position drive 7% growth in PrepaCyte Cord Blood sales. Expanding healthcare applications, strategic partnerships, and investments in R&D further fuel growth.

7. Detailed Products

Cord Blood Banking

Cryo-Cell International, Inc. offers cord blood banking services, which involves collecting and storing umbilical cord blood stem cells for potential future medical use.

Cord Tissue Banking

The company also offers cord tissue banking, which involves collecting and storing umbilical cord tissue for potential future use in regenerative medicine.

Dental Stem Cell Banking

Cryo-Cell International, Inc. provides dental stem cell banking services, which involves collecting and storing dental pulp stem cells from teeth.

Adipose Tissue Banking

The company offers adipose tissue banking, which involves collecting and storing adipose-derived stem cells from fat tissue.

8. Cryo-Cell International, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Cryo-Cell International, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the emergence of new technologies and competitors.

Bargaining Power Of Customers

Cryo-Cell International, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products and services are specialized, making it difficult for customers to switch to alternative providers.

Bargaining Power Of Suppliers

Cryo-Cell International, Inc. relies on a limited number of suppliers for its raw materials and equipment. While the company has some bargaining power due to its size and reputation, suppliers still have some leverage in negotiations.

Threat Of New Entrants

The cord blood banking industry has high barriers to entry, including significant capital expenditures and regulatory hurdles. This limits the threat of new entrants and allows Cryo-Cell International, Inc. to maintain its market position.

Intensity Of Rivalry

The cord blood banking industry is highly competitive, with several established players competing for market share. Cryo-Cell International, Inc. must continually innovate and differentiate itself to maintain its market position.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight -8059.07%
Debt Cost 6.50%
Equity Weight 8159.07%
Equity Cost 6.50%
WACC 6.50%
Leverage -98.77%

11. Quality Control: Cryo-Cell International, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
NHC

A-Score: 5.9/10

Value: 5.4

Growth: 4.8

Quality: 6.5

Yield: 5.0

Momentum: 6.0

Volatility: 8.0

1-Year Total Return ->

View Full Report
Stock-Card
Cryo-Cell International

A-Score: 4.8/10

Value: 6.4

Growth: 3.7

Quality: 6.4

Yield: 8.0

Momentum: 1.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Addus HomeCare

A-Score: 4.7/10

Value: 3.6

Growth: 7.8

Quality: 6.6

Yield: 0.0

Momentum: 3.0

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Cross Country Healthcare

A-Score: 4.7/10

Value: 6.6

Growth: 6.2

Quality: 4.6

Yield: 0.0

Momentum: 7.5

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
ASHS

A-Score: 3.8/10

Value: 9.6

Growth: 4.6

Quality: 3.5

Yield: 0.0

Momentum: 1.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Astrana Health

A-Score: 3.3/10

Value: 4.5

Growth: 7.3

Quality: 5.2

Yield: 0.0

Momentum: 0.0

Volatility: 2.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

4.0$

Current Price

4$

Potential

-0.00%

Expected Cash-Flows